Antonia Boyer

Antonia Boyer

Auto-generated profile, based on publicly available information

Antonia Boyer

University of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in Cancer Research Communications
Verified
Journal Article
Open access
YZYichi Zhang
Yichi Zhang
MOMarjaana Ojalill
Marjaana Ojalill
ABAntonia Boyer
Antonia Boyer
XCXiao Lei Chen
Xiao Lei Chen
ETElise Jeanne Marie Tahon
Elise Jeanne Marie Tahon
DSDavid D. Schlaepfer
David D. Schlaepfer
Tumor chemotherapy resistance arises frequently and limits high-grade serous ovarian cancer (HGSOC) patient survival. Focal adhesion kinase (FAK) is an intracellular protein–tyrosine kinase encoded by PTK2, a gene that is often gained in HGSOC. Canonically, FAK functions at the cell periphery. However, FAK also transits to the nucleus to modulate gene expression. We find that FAK is tyrosine-phosphorylated and nuclear-localized in tumors of patients with HGSOC surviving neoadjuvant platinum–paclitaxel chemotherapy and that FAK nuclear accumulation occurs upon subcytotoxic cisplatin exposure to ovarian tumor cells in vitro. FAK nuclear localization sequence (NLS) mutational inactivation resulted in tumor cell sensitization to cisplatin in vitro and in vivo relative to wild-type FAK-reconstituted ovarian tumor cells. Cisplatin cytotoxicity was associated with elevated ERK MAPK activation in FAK NLS− cells, cisplatin-stimulated ERK activation was also enhanced upon loss of FAK activity or expression, and cisplatin-stimulated cell death was prevented by an inhibitor of ERK signaling. MAPK phosphastase-1 (MKP1) negatively regulates ERK signaling, and cisplatin-induced MKP1 levels were significantly elevated in wild-type FAK compared with FAK NLS− ovarian tumor cells. Notably, small-molecule MKP1 inhibition enhanced both cisplatin-stimulated ERK phosphorylation and ovarian tumor cell death. Together, our results show that FAK expression, activity, and nuclear localization limit cisplatin cytotoxicity in part by regulating MKP1 levels and preventing noncanonical ERK/MAPK activation. Significance: FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras–Raf–MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type– and context-dependent.

17 September 2026 in Matrix Biology
Verified
Journal Article
Open access
MOMarjaana Ojalill
Marjaana Ojalill
THTerrance J. Haanen
Terrance J. Haanen
SKSafir Ullah Khan
Safir Ullah Khan
YZYichi Zhang
Yichi Zhang
ABAntonia Boyer
Antonia Boyer
DSDavid D. Schlaepfer
David D. Schlaepfer

17 September 2025 in bioRxiv
Verified
Preprint
Open access
XCXiao Lei Chen
Xiao Lei Chen
KTKevin M Tharp
Kevin M Tharp
MOMarjaana Ojalill
Marjaana Ojalill
DODuygu Ozmadenci
Duygu Ozmadenci
ABAntonia Boyer
Antonia Boyer
DSDavid D Schlaepfer
David D Schlaepfer
SUMMARY: High grade serous ovarian cancer (HGSOC) is the most lethal gynecologic malignancy in the USA due to chemo- and immuno-therapy resistance. We show that focal adhesion kinase (FAK) inhibition with ifebemtinib or tumor genetic FAK knockout (KO) in syngeneic ovarian tumor models stimulated resident large peritoneal macrophages to express CXCL13 chemokine and promoted B cell infiltration. Macrophage GATA6 inactivation prevented CXCL13 expression and enhanced FAK-KO tumor growth. Combining ifebemtinib with pegylated doxorubicin chemotherapy and anti-TIGIT immune checkpoint antibody extended survival with tumor-associated tertiary lymphoid structure formation. Mechanistically, FAK-KO heat-treated conditioned media contained exosomes enriched with omega-3 fatty acids which stimulated macrophage CXCL13 production. Ifebemtinib-treated tumors, FAK-KO exosomes, and purified eicosapentaenoic acid enhanced murine and human HGSOC-associated tumor macrophage reprogramming and CXCL13 expression. Overall, our studies define a tumor to macrophage signaling linkage via omega-3 exosome lipids supporting B cell recruitment, survival, immunotherapy enhancement, and actionable via small molecule FAK inhibition. eTOC Blurb: High-grade serous ovarian cancer remains difficult to treat due to therapy resistance. Chen et. al. reveal that tumor FAK inhibition educates macrophages to express CXCL13 associated with B cell infiltration - highlighting a new therapeutic pathway linking FAK inhibition, omega-3 fatty acid containing exosomes, and macrophage mediated anti-tumor activation. Bullet points: Genetic or small molecule FAK inhibition enhances ovarian tumor B cell infiltration Tumor FAK inhibition stimulates GATA6+ macrophages to make CXCL13 FAKi, pegylated doxorubicin and anti-TIGIT promote tertiary lymphoid structures Omega-3 fatty acids stimulate human HGSOC ascites macrophages to make CXCL13

20 December 2024
Verified
Other
Open access
YZYichi Zhang
Yichi Zhang
MOMarjaana Ojalill
Marjaana Ojalill
ABAntonia Boyer
Antonia Boyer
XCXiao Lei Chen
Xiao Lei Chen
ETElise Jeanne Marie Tahon
Elise Jeanne Marie Tahon
DSDavid D. Schlaepfer
David D. Schlaepfer
FAK nuclear localization supports KMF tumor cisplatin resistance in vivo with effects on downstream signaling. A, Experimental schematic: 7.5 million luciferase-expressing KMF FAK-WT or FAK-NLS− cells were intraperitoneally injected into C57Bl6 mice (day 0), and IVIS luciferase imaging at day 5 was used to randomize experimental groups (n = 8 each). Mice were administered saline or cisplatin (CP, 4 mg/kg) and imaged on the indicated days. B, Graphical presentation of IVIS tumor burden from day 5 to day 31 as expressed as total flux in photons per second. Experimental groups are FAK-WT saline (green), FAK-WT plus CP (red), FAK-NLS− saline (blue), and FAK-NLS− + CP (violet). Values are means ± SD (n = 8, *, P < 0.05). C, Experimental schematic (similar as described in A) with decreased and more frequent cisplatin (2 mg/kg) administration over a longer experimental period. D, Representative IVIS images of CP-treated FAK-WT and FAK-NLS− tumor-bearing mice on day 45. E, Graphical presentation of IVIS tumor burden from day 5 to day 45. Experimental groups are FAK-WT + CP (red) and FAK-NLS− + CP (violet). Values are means ± SD (n = 8, **, P < 0.01). F, Enumeration (trypan blue–negative) of peritoneal cells recovered after euthanasia. Box and whisker plots show the mean (±SD, *, P < 0.05) for FAK-WT (red) and FAK-NLS− (violet) tumor-bearing mice. G, Protein cell lysates were made from peritoneal collected cells from individual FAK-WT and FAK-NLS− tumor-bearing mice (n = 5 each, M1 to M5) and immunoblotted for FAK, β-tubulin, active ERK (pERK), total ERK, active p38 (pp38), and total p38 MAPK. Immunoblotting for active JNK (pJNK) and total JNK were from the same samples but independent gels. H, Image quantitation of pERK to total ERK ratio from samples in G. Values are means ± SD (n = 5 experimental points, **, P < 0.01). FAK-WT values set to 1 (dotted line).

3 April 2025
Verified
Other
Open access
YZYichi Zhang
Yichi Zhang
MOMarjaana Ojalill
Marjaana Ojalill
ABAntonia Boyer
Antonia Boyer
XCXiao Lei Chen
Xiao Lei Chen
ETElise Jeanne Marie Tahon
Elise Jeanne Marie Tahon
DSDavid D. Schlaepfer
David D. Schlaepfer
FAK KO and reexpression show that nuclear FAK promotes cisplatin but not paclitaxel resistance in human OVCAR3 cells. A, Immunoblots of cultured FAK KO OVCAR3 (clone AB21) and GFP-FAK-WT or FAK-NLS− reconstituted AB21 cells for HA-tag (at FAK C-terminal), FAK pY397, and β-tubulin as a loading control. B, FAK-WT, and FAK-NLS− OVCAR3 cells were evaluated for cisplatin cytotoxicity after 48 hours in culture. Shown is percent cell viability vs. cisplatin concentration (μmol/L, log10), and points are means of triplicate samples ± SD (n = 3 independent experiments). C, Determination of IC50 values to cisplatin as performed in B (***, P < 0.001). D, FAK-WT and FAK-NLS− OVCAR3 cells were evaluated for paclitaxel cytotoxicity (μmol/L, log10) after 48 hours in culture. E, Analysis of OVCAR3 FAK-WT and FAK-NLS− cells for growth in culture and (F) in the presence of 0.5 μmol/L cisplatin for 72 hours. Values are means ± SD from two independent experiments with triplicate points and FAK-WT values set to 1 (***, P < 0.001; ns not significant). G, Representative images of crystal violet–stained OVCAR3 FAK-WT and FAK-NLS− cell colonies formed in the presence of 0, 0.5, or 1.0 μmol/L cisplatin after 10 days. H, Quantitation of FAK-WT (green bars) and FAK-NLS− (blue bars) colony formation. Values are means ± SD from three independent experiments with triplicate points (*, P < 0.05).

3 April 2025
Verified
Other
Open access
YZYichi Zhang
Yichi Zhang
MOMarjaana Ojalill
Marjaana Ojalill
ABAntonia Boyer
Antonia Boyer
XCXiao Lei Chen
Xiao Lei Chen
ETElise Jeanne Marie Tahon
Elise Jeanne Marie Tahon
DSDavid D. Schlaepfer
David D. Schlaepfer
Tumor chemotherapy resistance arises frequently and limits high-grade serous ovarian cancer (HGSOC) patient survival. Focal adhesion kinase (FAK) is an intracellular protein–tyrosine kinase encoded by PTK2, a gene that is often gained in HGSOC. Canonically, FAK functions at the cell periphery. However, FAK also transits to the nucleus to modulate gene expression. We find that FAK is tyrosine-phosphorylated and nuclear-localized in tumors of patients with HGSOC surviving neoadjuvant platinum–paclitaxel chemotherapy and that FAK nuclear accumulation occurs upon subcytotoxic cisplatin exposure to ovarian tumor cells in vitro. FAK nuclear localization sequence (NLS) mutational inactivation resulted in tumor cell sensitization to cisplatin in vitro and in vivo relative to wild-type FAK-reconstituted ovarian tumor cells. Cisplatin cytotoxicity was associated with elevated ERK MAPK activation in FAK NLS− cells, cisplatin-stimulated ERK activation was also enhanced upon loss of FAK activity or expression, and cisplatin-stimulated cell death was prevented by an inhibitor of ERK signaling. MAPK phosphastase-1 (MKP1) negatively regulates ERK signaling, and cisplatin-induced MKP1 levels were significantly elevated in wild-type FAK compared with FAK NLS− ovarian tumor cells. Notably, small-molecule MKP1 inhibition enhanced both cisplatin-stimulated ERK phosphorylation and ovarian tumor cell death. Together, our results show that FAK expression, activity, and nuclear localization limit cisplatin cytotoxicity in part by regulating MKP1 levels and preventing noncanonical ERK/MAPK activation.Significance:FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras–Raf–MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type– and context-dependent.